Apnimed (APMD) News
NASDAQ: APMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.09-1.16 (-6.70%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
APMD news summary
We found 3 recent headlines mentioning Apnimed (APMD): 2 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Seeking Alpha. APMD is making an outsized move today, down 6.70% at $16.09, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Apnimed, Inc. GAAP EPS of -$1.05 misses by $0.46", was published by Seeking Alpha on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Apnimed headlines
- Apnimed, Inc. GAAP EPS of -$1.05 misses by $0.46Seeking Alpha
- Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateCAMBRIDGE, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and…GlobeNewswire
- Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management CHEST-led panel to showcase data from the Phase 3…GlobeNewswire